A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Entinostat (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Ipatasertib (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms MORPHEUS; MORPHEUS-HR+ Breast Cancer
- Sponsors Roche
- 14 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Sep 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 21 Dec 2022 Planned primary completion date changed from 7 Dec 2022 to 31 Dec 2023.